(CURE) Direxion Daily Healthcare - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25459Y8764 • Trading--Leveraged Equity
CURE: Pharmaceuticals, Biotechnology, Medical Equipment, Healthcare Providers
The Direxion Daily Healthcare Bull 3X Shares (NYSE ARCA:CURE) is a leveraged ETF designed to provide 3X daily returns relative to the performance of its underlying index, which tracks domestic healthcare companies. The fund allocates at least 80% of its net assets to financial instruments delivering 3X exposure to the index. The index spans key healthcare subsectors, including pharmaceuticals, healthcare equipment, biotechnology, healthcare providers, and life sciences. As a non-diversified fund, it can concentrate investments in a smaller range of securities. For more information, visit http://www.direxionfunds.com.
3-Month Forecast: Based on the technical and fundamental data, CURE is expected to trade within a range of $110-$120 over the next three months. The funds price of $115.25 is currently above its 20-day SMA ($110.06) and 50-day SMA ($103.15) but slightly below its 200-day SMA ($116.71), suggesting near-term bullish momentum with potential resistance near $117. The ATR of 3.61 indicates moderate daily volatility, while the AUM of $177.65M reflects sufficient liquidity to support its trading strategy.
Additional Sources for CURE ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CURE ETF Overview
Market Cap in USD | 177m |
Category | Trading--Leveraged Equity |
TER | 0.96% |
IPO / Inception | 2011-06-15 |
CURE ETF Ratings
Growth 5y | 50.4% |
Fundamental | - |
Dividend | 43.5% |
Rel. Strength Industry | -21.1 |
Analysts | - |
Fair Price Momentum | 100.52 USD |
Fair Price DCF | - |
CURE Dividends
Dividend Yield 12m | 0.98% |
Yield on Cost 5y | 3.37% |
Annual Growth 5y | 52.17% |
Payout Consistency | 40.2% |
CURE Growth Ratios
Growth Correlation 3m | 77.3% |
Growth Correlation 12m | -29.6% |
Growth Correlation 5y | 55.8% |
CAGR 5y | 26.66% |
CAGR/Max DD 5y | 0.57 |
Sharpe Ratio 12m | -0.49 |
Alpha | -25.31 |
Beta | 1.30 |
Volatility | 38.74% |
Current Volume | 21.5k |
Average Volume 20d | 44.4k |
As of March 15, 2025, the stock is trading at USD 104.31 with a total of 21,462 shares traded.
Over the past week, the price has changed by -8.63%, over one month by -0.91%, over three months by +9.72% and over the past year by -12.64%.
Partly, yes. Based on ValueRay Analyses, Direxion Daily Healthcare (NYSE ARCA:CURE) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 50.40 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CURE as of March 2025 is 100.52. This means that CURE is currently overvalued and has a potential downside of -3.63%.
Direxion Daily Healthcare has no consensus analysts rating.
According to ValueRays Forecast Model, CURE Direxion Daily Healthcare will be worth about 116.5 in March 2026. The stock is currently trading at 104.31. This means that the stock has a potential upside of +11.66%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 116.5 | 11.7% |